{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-041169","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.513771+00:00","generated_at":"2026-06-21T20:26:36.090745+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Roivant reports Q2 net loss $316M; VTAMA net revenue $5M; cash runway extended to H2 2025","bullets":["Net loss $315.9M ($0.42/share); non-GAAP net loss $226.8M improved from $290.0M YoY.","VTAMA net product revenue $5.0M; over 54,000 prescriptions by ~6,400 prescribers since launch.","Cash, equivalents and restricted cash $1.6B; runway extended to H2 2025 after offerings and Myovant proceeds.","Completed enrollment for brepocitinib SLE potentially registrational trial; data H2 2023.","Federal court denied Moderna's motion to dismiss Genevant/Arbutus IP suit; discovery proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-041169","json":"https://secwatch.observer/filing/0001140361-22-041169.json","markdown":"https://secwatch.observer/filing/0001140361-22-041169.md","text":"https://secwatch.observer/filing/0001140361-22-041169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122041169/0001140361-22-041169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122041169/brhc10044087_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:26:36.090745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e0654dc7e22d96f763ea619cd8094bf9fa24955","claim":"Roivant Sciences Ltd. reported fiscal quarter ended September 30, 2022 results: revenue $5.0 million.","evidence_excerpt":"Roivant reported VTAMA net product revenue of $5.0 million, representing a gross-to-net yield of approximately 12%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122041169/0001140361-22-041169-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal quarter ended September 30, 2022"},{"label":"Revenue","value":"$5.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}